Table 2.
Treatment and Outcomes
| Variable | No. With Data (of 283 Episodes) |
Value, Median (IQR) or % (No.) | |
|---|---|---|---|
| Duration of admission, d | 270 | 17 (11–22) | |
| Time from admission to 1st amphotericin dose, d | 159a | ||
| 0 | 11 (18) | ||
| 1 | 36 (57) | ||
| 2+ | 53 (84) | ||
| No. of missed amphotericin dosesa,b | 159a | ||
| 0 | 47 (74) | ||
| 1–2 | 32 (51) | ||
| 3+ | 21 (34) | ||
| Baseline CSF opening pressure recorded | 175 | 64 (112) | |
| No. of therapeutic lumbar puncturesc | |||
| 0 | 283 | 54 (154) | |
| 1 | 16 (46) | ||
| 2 | 11 (32) | ||
| 3 | 8 (23) | ||
| 4+ | 10 (28) | ||
| No. of monitoring full blood countsc | 283 | 1 (0–1) | |
| Median drop in hemoglobin, g/dLc | 146 | 2.0 (1.0–3.4) | |
| Median nadir hemoglobin, g/dLc | 161 | 8.9 (7.3–11.1) | |
| DAIDS Grade 3 anemia, <7.5 g/dLc | 161 | 29 (46) | |
| DAIDS Grade 4 anemia, <6.5 g/dLc | 161 | 17 (27) | |
| No. of monitoring electrolyte testsc | 283 | 2 (1–2) | |
| Median nadir serum potassium, mmol/Lc | 222 | 3.2 (2.8–3.9) | |
| DAIDS Grade 3 hypokalemiac | 222 | 9 (21) | |
| DAIDS Grade 4 hypokalemiac | 222 | 0 (0) | |
| No. of monitoring creatinine testsc | 283 | 2 (1–3) | |
| Median peak creatinine, µmol/Lc | 223 | 105 (73–147) | |
| Median % rise in creatininec | 194 | 53 (9–117) | |
| DAIDS Grade 3 creatinine risec | 223 | 10 (22) | |
| DAIDS Grade 4 creatinine risec | 223 | 1 (3) | |
| Outcomesd | |||
| Mortality at 2 wk, % (No.) | 233 | 26 (60) | |
| Mortality at 10 wk, % (No.) | 224 | 50 (112) | |
| Mortality at 1 y, % (No.) | 219 | 65 (142) | |
Abbreviations: CSF, cerebrospinal fluid; DAIDS, Division of AIDS; IQR, interquartile range.
aThese data were derived from paper records. Paper records were retrieved for 64% (180/283) of CM episodes, or 66% (156/236) of patients.
bThe number of missed doses was calculated from the first dose, by subtracting the actual number of doses given over 14 days from the recommended 14 doses, or, if the patient died before 14 doses, by subtracting the actual number of doses given from the number of days a patient was alive and should have received a dose.
cThese data were derived from electronic laboratory records. Note that the number of therapeutic lumbar punctures may be underestimated as CSF may not always have been sent to the laboratory for analysis, although it is routine hospital practice to do so.
dReported from date of first episode.